Navigation Links
Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008
Date:4/22/2008

due to

noncompliance. There were no serious adverse events or

discontinuations due to adverse events.

"These data show that the nitazoxanide lead-in phase prior to standard of care treatment can be reduced from 12 to 4 weeks with no apparent impact on virologic response rates," said Jean-Francois Rossignol, M.D., Director of the Romark Institute for Medical Research and lead author of the study.

-- Data from a poster presentation, "Randomized, Double-Blind Placebo-

Controlled Trial of Nitazoxanide in the Treatment of Patients with

Chronic Hepatitis C Genotype 4" showed that nitazoxanide monotherapy

for 24 weeks did not produce adverse events significantly different

from that of a placebo and suggest that monotherapy with nitazoxanide

may be effective in achieving SVR in a limited subset of patients with

low viral load.

In this randomized, controlled study, 50 treatment-nave patients with

chronic hepatitis C genotype 4 were randomized to receive one

nitazoxanide 500 mg tablet or a matching placebo tablet twice daily for

24 weeks. Baseline viral loads and other disease characteristics were

similar between groups. Seven of 23 patients (34%) receiving

nitazoxanide monotherapy achieved undetectable serum HCV RNA after 24

weeks of therapy, compared with 0 of 24 patients receiving placebo

(P=0.004). Four of these 7 treatment responders (4/23, or 17%) had a

SVR 24 weeks after completion of therapy. Patients not achieving

undetectable HCV RNA did not show significant reductions in viral load

or alanine aminotransferase (ALT) levels. Patients responding to

nitazoxanide treatment had lower viral loads at baseline. Adverse

events were typically mild to moderate and occurred with similar

frequency and severity between the nitazoxanide and placebo groups. <
'/>"/>

SOURCE Romark Laboratories
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Romark Laboratories Raises $18 Million in Institutional Financing
3. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 Passport Health, one of the ... has launched FluFree.com, a website designed to promote, educate ... For 20 years, Passport Health has provided its clients ... launch of FluFree.com is designed to address the growing ... of people who actually chose to get vaccinated. ...
(Date:9/30/2014)... 2014   Acutus Medical, Inc. (ACM), ... 3D Cardiac Chamber Imaging and Dipole Density Mapping system ... sustain complex cardiac arrhythmias, including atrial fibrillation, announced it ... its imaging/mapping system as well as bring to market ... Medical to complete work on the AcQMap TM ...
(Date:9/30/2014)... , Sept. 30, 2014 Headquartered in ... is a diversified company comprised of several specialized partners ... technology and the proven expertise of its team of ... wellness. WholeHealth Products, line of more than 10 professional ... and its more than 8 retail consumer tests is ...
Breaking Medicine Technology:Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 2Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 3Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 2Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 3WholeHealth Products Announces The Discovery Of The "Autism And Fragile X" Microwell And Rapid Diagnostic Test 2
... , ARDEE, Ireland, Nov. 19 Warner Chilcott ... its previously announced secondary offering of 20,000,000 of its ordinary ... share. The selling shareholders include funds affiliated with Bain ... CCMP Capital) and Thomas H. Lee Partners, L.P., certain other ...
... , ... leading global,supplier of active pharmaceutical ingredients (APIs), announced ... Safety Certification from,SafeBridge(R) Consultants, Inc. The Certification confirms ... potent active,pharmaceutical ingredients (APIs), and applies to specific ...
Cached Medicine Technology:Warner Chilcott Prices Secondary Equity Offering 2Warner Chilcott Prices Secondary Equity Offering 3Warner Chilcott Prices Secondary Equity Offering 4ScinoPharm Announces SafeBridge Potent Compound Safety Certification 2
(Date:9/30/2014)... A group of Americans is headed to a ... left unchecked, could create a catastrophic, global pandemic. No, it’s ... John Rogers, the Executive Director the Eugene Bell Foundation and ... disease most think mankind conquered long ago: tuberculosis. , “Tuberculosis, ... on the comeback in several countries - what’s especially disconcerting ...
(Date:9/30/2014)... TUESDAY, Sept. 30, 2014 (HealthDay News) -- Medicare should ... at high risk for the disease, a coalition of ... The coalition, which includes the Lung Cancer Alliance, the ... the American Cancer Society and the American Society of ... Monday to the U.S. Centers for Medicare & Medicaid ...
(Date:9/30/2014)... gene mutation that causes a rare premature aging disease ... the rapid, unstoppable cell division that makes cancer so ... and the U-M Health System recently discovered a protein ... which precious hematopoietic stem cells can,t regenerate and make ... prone to cancer and bone marrow failure. , ...
(Date:9/30/2014)... Healthpointe is proud to announce that ... and ankle reconstruction surgeries to assist patients with severe ... specializes in the diagnosis and treatment of sports medicine, ... also trained to perform advanced Foot and Ankle Reconstruction ... is also fluent in Spanish. , Reconstructive surgical procedures ...
(Date:9/30/2014)... September 30, 2014 Jiwa Law Corporation, a ... that it will now be offering free consultation for personal ... visit the law firm for the first time to meet ... be given the opportunity to understand what their rights are. ... with the client to explain to them what the law ...
Breaking Medicine News(10 mins):Health News:US Delegation Heads to North Korea to Combat Tuberculosis Epidemic 2Health News:Groups Call for Medicare Coverage of Lung Cancer Screening 2Health News:Disease decoded: Gene mutation may lead to development of new cancer drugs 2Health News:Fellowship-Trained and Board-Certified Orthopedic Specialist Now Performing Advanced Foot & Ankle Reconstruction Surgeries 2Health News:Fellowship-Trained and Board-Certified Orthopedic Specialist Now Performing Advanced Foot & Ankle Reconstruction Surgeries 3Health News:Jiwa Law Corporation Now Offers Personal Injury Consultation Without Any Charge 2
... Calif., April 22 DURECT,Corporation (Nasdaq: DRRX ... Executive Officer, will be presenting at the Morgan ... 2008 at 8:30 a.m. ET.,The conference is being ... (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ), A live ...
... Therapeutics,(Amex: CXM ) and its operating unit ... System will be featured on Science,Channel,s "Cool Stuff: ... will,feature InnerCool,s endovascular cooling during a 6-hour brain ... 25, 2008 at 8:00 p.m. (ET/PT). Please,visit ...
... prices have risen,sharply over the last 12 months, organic ... expected to continue in 2008, according to,the Organic Trade ... safer than conventional foods, they are also more expensive.,Because ... looking,to strike a balance between their desire to eat ...
... April 21, 2008 3M Health Care, a leader ... announces plans to introduce the 3M Rapid Detection Flu ... qualitative and objective electronic results in 15 minutes. , ... season, the Rapid Detection Flu Test quickly delivers objective ...
... GeneGo, Inc., the leading,provider of software and databases ... the Chinese University of Hong Kong,Pediatric department will ... drug targets for a large variety of diseases ... to license MetaCore, as well as,species-specific content for ...
... POUGHKEEPSIE, N.Y., April 22 Just in time ... ) is rolling,out a new line of high-end ... -- and the well-being of its customers., ... covers made of bamboo -- a renewable resource ...
Cached Medicine News:Health News:Cardium Announces InnerCool's Endovascular Cooling to be Featured on Science Channel's Series 'Cool Stuff: How It Works' 2Health News:Cardium Announces InnerCool's Endovascular Cooling to be Featured on Science Channel's Series 'Cool Stuff: How It Works' 3Health News:Cardium Announces InnerCool's Endovascular Cooling to be Featured on Science Channel's Series 'Cool Stuff: How It Works' 4Health News:Eat Well, Save Money: BJ's Offers Everyday Low Prices on Top Quality Organic Groceries, Natural Foods Versus Supermarket Prices 2Health News:Eat Well, Save Money: BJ's Offers Everyday Low Prices on Top Quality Organic Groceries, Natural Foods Versus Supermarket Prices 3Health News:3M Health Care announces new 3M Rapid Detection Flu A+B test 2Health News:GeneGo's First Customer in Hong Kong; The Chinese University of Hong Kong 2Health News:Bragada(R) Luxury Mattress, Inc. Goes Green 2
1 mm smooth 45 degrees angled jaws. Cross action serrated handle with polished finish....
14 mm oval solid lower plate and straight 9 mm serrated upper jaw. Locking thumb screw and serrated handle with polished finish....
Solid lower plate with outside width 28 mm. Open upper plate. Serrated handle with locking thumb screw and polished finish. Right....
Oval solid 17 mm wide lower plate. Open upper plate with inside dimensions 12 mm x 14 mm. Serrated handle with locking thumb screw and polished finish. Most popular size or model....
Medicine Products: